AU2014288857B2 - A pharmaceutical combination for the treatment of melanoma - Google Patents

A pharmaceutical combination for the treatment of melanoma Download PDF

Info

Publication number
AU2014288857B2
AU2014288857B2 AU2014288857A AU2014288857A AU2014288857B2 AU 2014288857 B2 AU2014288857 B2 AU 2014288857B2 AU 2014288857 A AU2014288857 A AU 2014288857A AU 2014288857 A AU2014288857 A AU 2014288857A AU 2014288857 B2 AU2014288857 B2 AU 2014288857B2
Authority
AU
Australia
Prior art keywords
melanoma
inhibitor
compound
braf
vemurafenib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014288857A
Other languages
English (en)
Other versions
AU2014288857A1 (en
Inventor
Veena Agarwal
Giridharan Periyasamy
Maggie Rathos
Sreesha SRINIVASA
Ankita SRIVASTAVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Enterprises Ltd
Original Assignee
Piramal Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Ltd filed Critical Piramal Enterprises Ltd
Publication of AU2014288857A1 publication Critical patent/AU2014288857A1/en
Application granted granted Critical
Publication of AU2014288857B2 publication Critical patent/AU2014288857B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014288857A 2013-07-12 2014-07-11 A pharmaceutical combination for the treatment of melanoma Active AU2014288857B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361845749P 2013-07-12 2013-07-12
US61/845,749 2013-07-12
PCT/IB2014/063022 WO2015004636A1 (en) 2013-07-12 2014-07-11 A pharmaceutical combination for the treatment of melanoma

Publications (2)

Publication Number Publication Date
AU2014288857A1 AU2014288857A1 (en) 2016-02-04
AU2014288857B2 true AU2014288857B2 (en) 2019-03-14

Family

ID=52279411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014288857A Active AU2014288857B2 (en) 2013-07-12 2014-07-11 A pharmaceutical combination for the treatment of melanoma

Country Status (12)

Country Link
US (4) US11007174B2 (enExample)
EP (1) EP3019166B1 (enExample)
JP (5) JP6568060B2 (enExample)
CN (3) CN105530931B (enExample)
AR (1) AR096892A1 (enExample)
AU (1) AU2014288857B2 (enExample)
CA (1) CA2917742C (enExample)
DK (1) DK3019166T3 (enExample)
ES (1) ES2733929T3 (enExample)
IL (1) IL243572B (enExample)
TW (4) TWI839690B (enExample)
WO (1) WO2015004636A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI839690B (zh) 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
JP7033451B2 (ja) * 2015-06-05 2022-03-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ Ｐａｃ－１併用療法
TWI804919B (zh) * 2015-06-30 2023-06-11 美商建南德克公司 含藥物之立即釋放錠劑及形成該錠劑的方法
AU2017232496B2 (en) * 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018213302A1 (en) * 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
CA3082575A1 (en) 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
CN107827726B (zh) * 2017-11-28 2020-09-15 辽宁中医药大学 马齿苋中化合物Oleracone E及其提取分离方法
CN108591464B (zh) * 2018-06-28 2020-06-23 宁波奥克斯高科技有限公司 一种气体绝缘开关柜用密封结构
CA3114385A1 (en) * 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
IL286993B2 (en) 2019-04-11 2026-04-01 Mei Pharma Inc Polymorphs of vorocicliv and methods for their preparation and use
WO2021229439A1 (en) * 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor
CN112168821B (zh) * 2020-11-09 2022-10-14 中南大学湘雅医院 一种治疗维罗非尼耐药的黑色素瘤的联合用药物及其应用
AU2021381423A1 (en) * 2020-11-19 2023-06-22 Mei Pharma, Inc. Treatment of kras mutant cancers
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164232B (enExample) 1986-04-11 1989-02-04 Hoechst India
US5116954A (en) 1988-04-06 1992-05-26 Lipha, Lyonnaise Industrielle Pharmaceutique Pharmaceutically useful flavonoic compounds containing at least one substituent on the benzopyranone ring moiety
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
US5723313A (en) 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
US6281223B1 (en) 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
JP2003531899A (ja) 2000-05-03 2003-10-28 エルジー ライフ サイエンス リミテッド ３−ヒドロキシクロメン−４−オン構造を有するｃｄｋ阻害剤
CA2413702A1 (en) 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
US7915301B2 (en) 2002-07-08 2011-03-29 Piramal Life Science Limited Inhibitors of cyclin dependent kinases and their use
US7271193B2 (en) * 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7884127B2 (en) 2002-07-08 2011-02-08 Pirimal Life Sciences Ltd. Inhibitors of cyclin dependent kinases and their use
CA2502979A1 (en) 2002-11-06 2004-05-21 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
ZA200604579B (en) 2003-12-08 2007-10-31 Univ Arizona Synergistic anti-cancer compositions
CN101171241A (zh) 2005-03-11 2008-04-30 密执安州立大学董事会 抗细胞凋亡的bcl-2家族成员的色烯-4-酮抑制剂及其应用
MY153898A (en) * 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
KR101209397B1 (ko) * 2006-06-21 2012-12-06 피라말 라이프 사이언시스 리미티드 증식성 질환 치료용 광학이성적으로 순수한, 증식성 질환 치료용 플라본 유도체 및 이의 제조방법
CA2658215C (en) 2006-07-07 2013-08-27 Piramal Life Sciences Limited An enantioselective synthesis of pyrrolidines-substituted flavones
GB0706633D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd Combination
CA2687204C (en) 2007-05-15 2015-11-24 Piramal Life Sciences Limited A synergistic pharmaceutical combination for the treatment of cancer
US20100152129A1 (en) * 2008-03-31 2010-06-17 Periyasamy Giridharan Novel synergistic combination of gemcitabine with P276-00 or P1446A in treatment of cancer
TWI461194B (zh) 2009-05-05 2014-11-21 Piramal Entpr Ltd 吡咯啶取代黃酮作為輻射致敏劑
MX2012009830A (es) 2010-02-26 2013-02-11 Piramal Entpr Ltd Flavonas sustituidas de pirrolidina para el tratamiento de desordenes inflamatorios.
CN101841463B (zh) * 2010-03-05 2012-05-16 清华大学 基于sctp的多路径并发传输方法
JP5903433B2 (ja) * 2010-08-26 2016-04-13 ノバルティス アーゲー 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ
CN104689318A (zh) 2010-11-19 2015-06-10 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法
BR112013012313A2 (pt) 2010-11-19 2019-09-24 Piramal Enterprises Limited combinação farmacêutica de paclitaxel e um inibidor de cdk
WO2012123889A1 (en) * 2011-03-14 2012-09-20 Piramal Healthcare Limited A synergistic pharmaceutical combination for the treatment of pancreatic cancer
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
AU2012274990A1 (en) 2011-06-24 2014-02-06 Piramal Enterprises Limited Compounds for the treatment of cancers associated with human papillomavirus
TW201338774A (zh) 2012-01-13 2013-10-01 Piramal Entpr Ltd 口腔粘膜炎預防或治療化合物
WO2014049515A1 (en) 2012-09-25 2014-04-03 Piramal Enterprises Limited Pyrrolidine substituted flavones for treatment of renal cystic diseases
WO2014128523A1 (en) 2013-02-19 2014-08-28 Piramal Enterprises Limited A process for preparation of an intermediate of the pyrrolidine substituted flavones
TWI839690B (zh) 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
EP3148532B1 (en) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmaceutical combination comprising a cdk inhibitor and a thioredoxin reductase inhibitor for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation", (2013-04-25), pages 1 - 6 URL: http://clinicaltrials.gov/archive/NCT01841463/2013_04_25 *

Also Published As

Publication number Publication date
CN111053768A (zh) 2020-04-24
TWI680760B (zh) 2020-01-01
CN117731786A (zh) 2024-03-22
WO2015004636A1 (en) 2015-01-15
TW202233177A (zh) 2022-09-01
JP2022068335A (ja) 2022-05-09
TW202031253A (zh) 2020-09-01
EP3019166B1 (en) 2019-05-08
IL243572A0 (en) 2016-02-29
EP3019166A1 (en) 2016-05-18
DK3019166T3 (da) 2019-07-29
IL243572B (en) 2019-10-31
AU2014288857A1 (en) 2016-02-04
TW201534297A (zh) 2015-09-16
JP2021001186A (ja) 2021-01-07
US20160136132A1 (en) 2016-05-19
CA2917742C (en) 2020-04-14
US20210393589A1 (en) 2021-12-23
JP2024037891A (ja) 2024-03-19
TWI839690B (zh) 2024-04-21
JP7799508B2 (ja) 2026-01-15
CN105530931B (zh) 2019-11-08
CN105530931A (zh) 2016-04-27
CN111053768B (zh) 2023-12-12
US20190282544A1 (en) 2019-09-19
US12383530B2 (en) 2025-08-12
JP2016525097A (ja) 2016-08-22
US11007174B2 (en) 2021-05-18
ES2733929T3 (es) 2019-12-03
AR096892A1 (es) 2016-02-03
EP3019166A4 (en) 2017-04-19
CA2917742A1 (en) 2015-01-15
TW202502325A (zh) 2025-01-16
JP2019206565A (ja) 2019-12-05
US20240165076A1 (en) 2024-05-23
JP6568060B2 (ja) 2019-08-28
US11839591B2 (en) 2023-12-12

Similar Documents

Publication Publication Date Title
US12383530B2 (en) Pharmaceutical combination for the treatment of melanoma
US20250332145A1 (en) Pharmaceutical combination for the treatment of cancer
US10383847B2 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
AU2024200650A1 (en) Therapeutic benefit of suboptimally administered chemical compounds
CN107249638A (zh) 阿匹莫德用于治疗肾癌
KR20240051953A (ko) Pi3k 이소형 알파를 억제하는 화합물 및 암 치료 방법
US9802948B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
TW201242597A (en) A synergistic pharmaceutical combination for the treatment of pancreatic cancer
EP1667719B1 (en) Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
HK40102341A (en) A pharmaceutical combination for the treatment of melanoma
HK1224936A1 (en) A pharmaceutical combination for the treatment of melanoma
HK1224936B (en) A pharmaceutical combination for the treatment of melanoma
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
RU2687107C1 (ru) Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
CA3198190A1 (en) Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers
HK1170667A (en) Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)